CN102321029A - Ornidazole compound and novel preparation method thereof - Google Patents

Ornidazole compound and novel preparation method thereof Download PDF

Info

Publication number
CN102321029A
CN102321029A CN201110198551A CN201110198551A CN102321029A CN 102321029 A CN102321029 A CN 102321029A CN 201110198551 A CN201110198551 A CN 201110198551A CN 201110198551 A CN201110198551 A CN 201110198551A CN 102321029 A CN102321029 A CN 102321029A
Authority
CN
China
Prior art keywords
ornidazole
purification
purified
reduced pressure
under reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201110198551A
Other languages
Chinese (zh)
Other versions
CN102321029B (en
Inventor
杨明贵
董林青
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HAINAN MEILAN SHIKE PHARMACEUTICAL CO Ltd
Original Assignee
HAINAN MEILAN SHIKE PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HAINAN MEILAN SHIKE PHARMACEUTICAL CO Ltd filed Critical HAINAN MEILAN SHIKE PHARMACEUTICAL CO Ltd
Priority to CN 201110198551 priority Critical patent/CN102321029B/en
Publication of CN102321029A publication Critical patent/CN102321029A/en
Application granted granted Critical
Publication of CN102321029B publication Critical patent/CN102321029B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to an ornidazole compound which is prepared in a method comprising the following steps: (1) a certain amount of ornidazole crude is dissolved in an organic solvent, active carbon is added for adsorption and filtration, filtrate is collected, pressure is reduced for concentration, and then primarily purified ornidazole is obtained; (2) the primarily purified ornidazole is separated and purified by a preparation type chromatographic column, eluent is collected, pressure is reduced for concentration, and then secondarily purified ornidazole is obtained; and (3) pure water is added into a concentrated solution, crystallization is carried out, and precipitated crystals are centrifugally washed and dried to obtain thirdly purified ornidazole. The ornidazole prepared in the method has high purity, the toxic and side effects of anaerobic bacteria and trichomonad resisting drugs are reduced, the product quality of preparations is improved, and the method is suitable for industrial mass production.

Description

A kind of ornidazole compound and new preparation method thereof
Technical field
The present invention relates to a kind of ornidazole compound, can obtain highly purified ornidazole, belong to medical technical field through its method for making.
Background technology
Ornidazole (Ornidazole), white or little yellow crystalline powder, chemical name: 1-(3-chloro-2-hydroxypropyl)-2-methyl-5-nitro imidazoles, molecular formula: C 7H 10ClN 3O 3, molecular weight: 219.63, structural formula is:
Figure BDA0000075933340000011
Ornidazole is behind metronidazole and tinidazole; The anerobes and the anti-trichomonal medicine that went on the market in Germany first by Switzerland Roche Holding Ag in 1977; Mechanism of its performance anti-microbial effect possibly be: in oxygen-free environment, be reduced into amino or formation through radical and cellular constituent interaction through the nitro in its molecule, thereby cause the death of mikrobe; Ornidazole is used for treatment and bites the caused multiple infection of responsive anerobes such as knitting dimension bacterium, gum genera bacillus by bacteroide fragilis, bacteroides disiens, ovum garden bacterioide, bacteroides thetaiotaomicron, bacteroides vulgatus, clostridium, Eubacterium, dyspepsiacoccus and peptostreptococcus, helicobacter pylori, bacaeroides melaninogenicus, fusobacterium, CO2 clinically.
US3435049A at first discloses the ornidazole by the toluene recrystallization; Mainly contain 3 synthetic routes at present: route 1 with 2-methyl-5-nitro imidazoles and two (3-chloro-2-hydroxypropyl) sulfuric ester reactions, obtains 1-(2; The 3-epoxypropyl)-2-methyl-5-nitro imidazoles; After open loop under the concentrated hydrochloric acid effect, obtain the ornidazole bullion then, use the toluene recrystallization, but raw material is not easy to obtain; Route 2, with 2-methyl-5-nitro imidazoles and epoxy methyl chloride at AlCl 3Effect reaction down obtains, re-crystallizing in ethyl acetate, but reaction must be strict anhydrous; Route 3 reacts in formic acid with 2-methyl-5-nitro imidazoles and epoxy chloropropane and to obtain.
The compound method of the ornidazole of " Chinese Journal of Pharmaceuticals " 2004,35 (II) report, yield has only 51%.The preparation method of a kind of ornidazole optical enantiomorph of introducing among the Chinese patent CN1651415A accomplishes through the experiment of six steps, and comparatively complicated, agents useful for same is more, and cost is high, and yield is lower.Chinese patent CN1800166A provides the preparation and the purification process of ornidazole optical enantiomorph; With 2-methyl-5-nitro imidazoles with have optically active epichlorohydrin reaction; Get intermediate product hydrolysis again, acidifying, neutralization; Promptly get optically active ornidazole, repurity gets pure article S-(-)-ornidazole or R-(+)-ornidazole.
Chinese patent CN1923817A discloses the compound method of ornidazole, uses the lewis acid catalysis, and its productive rate is generally less than 60%.CN101633643A provides a kind of ornidazole compound of variation route, through 2-methyl-5-nitro imidazoles and epoxy chloropropane are reacted in solvent, adds mixture of ice and water, regulates the pH value, and recrystallization obtains ornidazole.
Can find out that the method or the step of prior art are various, are not suitable for industrial production; Perhaps yield is lower, has expended a large amount of raw materials, causes the high enterprise of cost, or has used toxic solvents, causes the toxic residue of medicine, has influenced the formulation products quality.
In addition, deposit improper or shelf-time when long at compound, can cause active constituents of medicine content to reduce, color and luster is strengthened, and the related substance for example content of 2-methyl-5-nitro imidazoles raises.In some cases, because controlling of production process is improper, cause pharmaceutical purity also undesirable.Therefore prior art does not disclose special purification process to this, be necessary underproof product or slightly further carry out purifying, with high yield highly purified compound is provided.This area presses for the compound method that works out a kind of low cost, yield height, is applicable to the ornidazole of big production, to overcome above-mentioned shortcoming.
The technical issues that need to address of the present invention are the deficiencies that overcome prior art, and a kind of purification process of ornidazole compound is provided, and this method is simple, and product purity is high, and yield is high, is easy to suitability for industrialized production.
Summary of the invention
In order to overcome the defective of above-mentioned prior art, improve ornidazole purity, reduce the residual of toxic solvents; The invention provides a kind of purification process of ornidazole compound; Preparing method of the present invention can improve the formulation products quality, reduces toxic side effect, is suitable for industrialized production.
Aspect separation and purification; Know in the specificity owing to compound aspect the high yield compound of acquisition high purity with those skilled in the art know that and face all difficulties; All these just can be expected by the theory of existing general separation and purification absolutely not solution need overcome many difficult problems.
Generally speaking, conventional separation method has, and for example comprises the cooling of reaction mixture, then through filtering the crystalline method of collecting; Comprise adding thermal crystalline, and with for example methyl alcohol or the washing of its analogue of alcohol, distillation is except that desolvating and cooling off the crystalline method that obtains then; Solvent extration; Dilution method; Recrystallization method; Column chromatography; Methods such as preparation thin-layer chromatography.
The applicant is on the basis of a large amount of existing documents; Experiment through a large amount of screenings; Find above-mentioned document and general method for purifying and separating for example method such as crystallization be difficult to obtain the compound of high purity high yield, and various separation purification method and multiple conditional parameter possibly exist varied associativity and unpredictability.The inventor is through long-term conscientious research, and after Combination application specific method and parameters optimization, accident has been found a kind of purification process of ornidazole compound, has obtained the highly purified product of high yield astoundingly.
The ornidazole that process for purification provided by the invention was directed against is prepared ornidazole bullion of present known compound method or commercially available ornidazole bulk drug, below is referred to as the ornidazole bullion that the present invention adopts.
The inventor through comprising the preparation method of following treatment step, can increase substantially the purity of raw material ornidazole through discovering:
(1) with a certain amount of ornidazole dissolving crude product in organic solvent, add charcoal absorption, filter, collect filtrating, concentrating under reduced pressure obtains the ornidazole of elementary purification;
(2) above-mentioned liquid concentrator is carried out separation and purification with the preparative scale chromatography post, collect elutriant, concentrating under reduced pressure obtains the ornidazole that secondary is purified;
(3) in liquid concentrator, add pure water, stir, carry out crystallization, with the crystal centrifuge washing of separating out, drying, the ornidazole of three grades of purifications of acquisition.
The following specifically describes the present invention.
Step 1
In organic solvent, charcoal absorption is filtered with a certain amount of ornidazole dissolving crude product, collects filtrating, and concentrating under reduced pressure obtains the ornidazole of elementary purification.
The organic solvent that with water dissolve each other of described organic solvent for dissolving ornidazole.
Said organic solvent is selected from the lower alcohol or the non-alcohols polar solvent that can make the ornidazole homogenizing, is selected from one or more the mixture in methyl alcohol, ethanol, propyl alcohol, acetone, acetonitrile, tetramethylene sulfone, hydroxy-propionic acid, the terepthaloyl moietie, is preferably ethanol.
In one aspect of the invention, the separation and the purification process of medicine comprise adsorption method, as using gac.Unfortunately, except removing color and other unwanted material, gac also irreversibly adsorbs medicine, and this causes productive rate obviously to reduce.The present invention confirms that gac can be used for the preparation method of ornidazole, and the amount of wherein said adding gac is the 0.1-0.5% (g/ml) of overall solution volume.
Above-mentioned described preparation method, the temperature of wherein said whip attachment are 40-50 ℃, and the time of whip attachment is 10-15 minute.
The possible reason of effect that step 1 of the present invention adopts charcoal absorption why can reach purification is: the larger molecular organicses such as coloring matter of gac molecule in can adsorbent solution.
Step 2
Carry out separation and purification with the preparative scale chromatography post, collect elutriant, concentrating under reduced pressure obtains the ornidazole that secondary is purified.
Generally speaking, contain the solvent of introducing in the preparation process, various raw material, intermediate product in the ornidazole, owing to drawing the moist moisture of bringing into; Bacterial endotoxin; And various inorganicss and heavy metal etc., these materials exist with the form of impurity, have influenced the purity of ornidazole.The present invention uses the separation and purification function of preparative scale chromatography post, and the part of the ornidazole in the solution is partly separated with impurity, reaches the purpose of purification ornidazole.
The applicant is through long-term conscientious big quantity research; In the separation and purification process; Screened various filler chromatographic columns such as silica gel, aluminum oxide or macroporous resin, for example the particle diameter of silica gel is 45-250 μ m, the silica gel of aperture for
Figure BDA0000075933340000061
; Aluminum oxide or neutral alumina particle diameter are aluminum oxide or the neutral alumina of 18-200 μ m; The macroporous resin model is macroporous resins such as AmberliteXAD-6, AmberliteXAD-7, AmberliteXAD-8, Diaion HP2MG, GDX-501, HPD400, HPD450, HPD750, AmberliteXAD-9, AmberliteXAD-10, GDX-401, GDX-601, AB-8; The unexpected application macroporous resin of finding of the inventor does not have clear improvement to product gas purity; Silica gel is also undesirable; And special-purpose neutral alumina not only can fully adsorb composition impurity and other pigment in the upper prop thing; Also these article purifying is had original windfall effect, and operation is simpler and easy.
In one aspect of the invention, said stationary phase is that particle diameter is 18-200 μ m, and the aperture is 50-200 μ m for pore neutral alumina or the particle diameter of about 6nm, and the aperture is 6nm, the column chromatography special neutral aluminum oxide of pH 7.0 or pH 7.5.
In one aspect of the invention, neutral alumina can be for example for the ICNallumina N preferable particle size of supplier ICN be 18-63 μ m, and the aperture is the pore neutral alumina of 6nm; PH 7.5; Preferable particle size is 18-32 μ m, and the aperture is the pore neutral alumina of 6nm, and pH 7.5.Perhaps, neutral alumina for example is a supplier Baker column chromatography special neutral aluminum oxide, and particle diameter is 50-200 μ m, and the aperture is 6nm, pH 7.0 or pH 7.5.
In one aspect of the invention, as preferably, the quality of each purifying medicine is 1 with the ratio of the quality of chromatographic column filler: 10-200, the preferred mass ratio is 1: 15-100.The consumption of moving phase is as long as satisfy the complete basically wash-out of medicine; Flow point Fractional Collections behind the wash-out; The content of the flow point Chinese traditional medicine of different sections is different, in order to obtain highly purified medicine (for example purity is greater than 99.5%), needs medicament contg is merged greater than 85% flow point; Preferably medicament contg is incorporated in one aspect of the present invention greater than 90% flow point, the required purity that obtains in the methods of the invention depends on the amount of impurity and the operating environment of chromatographic column to a certain extent.The selection of organic solvent and consumption must be controlled in moving phase, make can not come out the impurity wash-out prematurely.Generally speaking, the chromatographic column of the used chromatographic column of the present invention comprises that diameter is about 0.1 to about 20cm, is preferably 3cm at least.The chromatogram column length scope is preferably about 10 centimetres to about 100 centimetres in this method, and more preferably length range is about 20 centimetres to about 30 centimetres, and most preferred length is 25 centimetres.
Preparing method of the present invention, wherein the moving phase used of chromatographic column is 3: 7 the acetonitrile and the mixing solutions of water as volume ratio, and fixed phase stuffing is selected from neutral alumina, and flow velocity 0.1-2ml/min, column temperature are room temperature, wavelength 312nm.
Preparing method of the present invention, wherein the temperature of concentrating under reduced pressure is 50 ℃.
Step 3
In liquid concentrator, add pure water, stir, carry out crystallization, with the crystal centrifuge washing of separating out, drying makes ornidazole.
Preparing method of the present invention, wherein said ornidazole crystallization is dry with solid drier.Preparing method of the present invention, wherein said solid drier is selected from a kind of in anhydrous magnesium sulfate, Calcium Chloride Powder Anhydrous, anhydrous calciumsulphate and the activated alumina, preferred Calcium Chloride Powder Anhydrous.
In view of the powder flowbility of ornidazole, intrinsic dissolution rate, Pickering property and preparation operability huge to the influence of its active performance and the preparation prepared, and the ornidazole that purity is largely increased dissolution rate, the property prepared and stable aspect also corresponding obvious improvement.
Therefore, be fit to fully be mixed with according to the inventive method purified ornidazole and be used to treat the medicine of biting the caused multiple infection of responsive anerobes such as knitting dimension bacterium, gum genera bacillus by bacteroide fragilis, bacteroides disiens, ovum garden bacterioide, bacteroides thetaiotaomicron, bacteroides vulgatus, clostridium, Eubacterium, dyspepsiacoccus and peptostreptococcus, helicobacter pylori, bacaeroides melaninogenicus, fusobacterium, CO2.
The present invention has fundamentally changed the lower present situation of domestic and international ornidazole material purity, has solved the difficult problem that rough ornidazole and ornidazole bulk drug face, and has improved because a series of clinical adverse of the more initiation of impurity.
In addition, the inventive method purity is high, obtains purity and is not less than 99.6%.Its method for detecting purity is known in the art, but High performance liquid chromatography, for example referring to Liang Xiaoqing etc., " Chinese Journal of Pharmaceuticals " 2002,33 (02), the HPL C assay method of ornidazole injection liquid.Adopting Lichrospher-C1 8 chromatographic columns, is moving phase with methanol-water (30: 70), detects wavelength 312nm.
Each reference that the application quoted is incorporated herein by reference at this in full.
As preferably, the present invention provides a kind of process for purification of ornidazole, it is characterized in that this method comprises the steps:
(1) with a certain amount of ornidazole dissolving crude product in the organic solvent that dissolves each other with water of 4-10 times of weight, add the gac that accounts for overall solution volume 0.1-0.5% (g/ml), 40-50 ℃ whip attachment 10-15 minute; Filter decarburization; Collect filtrating, concentrating under reduced pressure obtains the ornidazole of elementary purification;
(2) mix the ornidazole of above-mentioned elementary purification thoroughly back with an amount of fixed phase stuffing and go up appearance, carry out separation and purification with preparation type neutral alumina chromatographic column, collect the ornidazole elutriant, 40~60 ℃ of concentrating under reduced pressure obtain the ornidazole that secondary is purified;
(3) in above-mentioned liquid concentrator, add pure water, carry out crystallization, the crystal centrifuge washing of separating out is dry through solid drier, the ornidazole of three grades of purifications of acquisition.
The ornidazole that relates in one aspect to the inventive method preparation of the present invention is used for the purposes of anaerobe resistant and anti-trichomonal medicine in preparation.
Embodiment
Below come further to explain or explanation content of the present invention through embodiment.But the embodiment that is provided should not be understood that protection domain of the present invention is constituted restriction.
Making with extra care of embodiment 1 ornidazole
The ornidazole dissolving crude product of 10g purity 96.52% in 40ml ethanol, is stirred, it is dissolved fully, add the gac of 0.2g then, 40 ℃ of whip attachment 15 minutes are filtered decarburization, collect filtrating; Add the 10g aluminum oxide again after concentrating and stir, fling to the chromatographic column upper end that is added to preparation behind the solvent, with the preparative scale chromatography post filtrating is carried out separation and purification then; Wherein the moving phase used of chromatographic column is 3: 7 the acetonitrile and the mixing solutions of water as volume ratio, and flow velocity 0.1ml/min, fixed phase stuffing are that particle diameter is that 18-32 μ m, aperture are the ICN allumina N neutral alumina of 6nm; Column temperature is a room temperature; Wavelength 312nm collects elutriant, 50 ℃ of concentrating under reduced pressure; In liquid concentrator, add pure water, stir, crystallization, 500rpm is centrifugal, and Calcium Chloride Powder Anhydrous is dry, gets ornidazole 9.23g, yield 95.63%, purity 99.63%, 77.5 ℃ of mp.
Making with extra care of comparative example's 1 ornidazole
The ornidazole dissolving crude product of 10g purity 96.52% in 40ml ethanol, is stirred, it is dissolved fully, add the gac of 0.2g then, 40 ℃ of whip attachment 15 minutes are filtered decarburization, collect filtrating; Add 10g silica gel again after concentrating and stir, fling to the chromatographic column upper end that is added to preparation behind the solvent, with the preparative scale chromatography post filtrating is carried out separation and purification then; Wherein the moving phase used of chromatographic column is 3: 7 the acetonitrile and the mixing solutions of water as volume ratio, and flow velocity 0.1ml/min, fixed phase stuffing are that particle diameter is that 18-32 μ m, aperture are that the AmberliteXAD-6 type macroporous resin model of 6nm does; Column temperature is a room temperature; Wavelength 312nm collects elutriant, 50 ℃ of concentrating under reduced pressure; In liquid concentrator, add pure water, stir, crystallization, 500rpm is centrifugal, and Calcium Chloride Powder Anhydrous is dry, gets ornidazole 8.93g, yield 92.52%, purity 98.63%, mp 77-78 ℃.
Making with extra care of embodiment 2 ornidazoles
The ornidazole dissolving crude product of 10g purity 96.52% in 100ml ethanol, is stirred, it is dissolved fully, add the gac of 0.1g then, 50 ℃ of whip attachment 10 minutes are filtered decarburization, collect filtrating; Add the 10g aluminum oxide again after concentrating and stir, fling to the chromatographic column upper end that is added to preparation behind the solvent, with the preparative scale chromatography post filtrating is carried out separation and purification then; Wherein the moving phase used of chromatographic column is 3: 7 the acetonitrile and the mixing solutions of water as volume ratio, and flow velocity 2ml/min, fixed phase stuffing are particle diameter 50-200 μ m; The Baker column chromatography special neutral aluminum oxide of aperture 6nm, column temperature is a room temperature, wavelength 312nm; Collect elutriant, 50 ℃ of concentrating under reduced pressure; In liquid concentrator, add pure water, stir, crystallization, 500rpm is centrifugal, and Calcium Chloride Powder Anhydrous is dry, gets ornidazole 9.27g, yield 96.04%, purity 99.7%, 78 ℃ of mp.
Making with extra care of comparative example's 2 ornidazoles
The ornidazole dissolving crude product of 10g purity 96.52% in 100ml ethanol, is stirred, it is dissolved fully, add the gac of 0.1g then, 50 ℃ of whip attachment 10 minutes are filtered decarburization, collect filtrating; Add 10g silica gel again after concentrating and stir, fling to the chromatographic column upper end that is added to preparation behind the solvent, with the preparative scale chromatography post filtrating is carried out separation and purification then; Wherein the moving phase used of chromatographic column is 3: 7 the acetonitrile and the mixing solutions of water as volume ratio, and flow velocity 2ml/min, fixed phase stuffing are particle diameter 50-200 μ m; The silica gel of aperture 6nm, column temperature are room temperature, wavelength 312nm; Collect elutriant, 50 ℃ of concentrating under reduced pressure; In liquid concentrator, add pure water, stir, crystallization, 500rpm is centrifugal, and Calcium Chloride Powder Anhydrous is dry, gets ornidazole 8.57g, yield 88.79%, purity 98.97%, mp 77-78 ℃.
Making with extra care of embodiment 3 ornidazoles
The ornidazole dissolving crude product of 15g purity 96.52% in 120ml ethanol, is stirred, it is dissolved fully, add the gac of 0.4g then, 45 ℃ of whip attachment 10 minutes are filtered decarburization, collect filtrating; Add the 15g aluminum oxide again after concentrating and stir, fling to the chromatographic column upper end that is added to preparation behind the solvent, with the preparative scale chromatography post filtrating is carried out separation and purification then; Wherein the moving phase used of chromatographic column is 3: 7 the acetonitrile and the mixing solutions of water as volume ratio, and flow velocity 1ml/min, fixed phase stuffing are that particle diameter is that 18-32 μ m, aperture are the ICN allumina N neutral alumina of 6nm; Column temperature is a room temperature; Wavelength 312nm collects elutriant, 50 ℃ of concentrating under reduced pressure; In liquid concentrator, add pure water, stir, crystallization, 500rpm is centrifugal, and Calcium Chloride Powder Anhydrous is dry, gets ornidazole 9.36g, yield 96.97%, purity 99.78%, mp77.5 ℃.
Making with extra care of comparative example's 3 ornidazoles
The ornidazole dissolving crude product of 15g purity 96.52% in 120ml ethanol, is stirred, it is dissolved fully, add the gac of 0.4g then, 45 ℃ of whip attachment 10 minutes are filtered decarburization, collect filtrating; Add 15g after concentrating again and stir, be added to the macroporous adsorptive resins upper end after flinging to solvent, water, 3: 7 acetonitrile and the mixing solutions wash-out of water successively, flow velocity 1ml/min, collection elutriant, 50 ℃ of concentrating under reduced pressure through pretreated AB-8 resin; In liquid concentrator, add pure water, stir, crystallization, 500rpm is centrifugal, and Calcium Chloride Powder Anhydrous is dry, gets ornidazole 8.36g, yield 86.61%, purity 99.15%, mp 77-78 ℃.
Making with extra care of embodiment 4 ornidazoles
The ornidazole dissolving crude product of 15g purity 96.52% in 120ml ethanol, is stirred, it is dissolved fully, add the gac of 0.3g then, 45 ℃ of whip attachment 15 minutes are filtered decarburization, collect filtrating; Add the 15g aluminum oxide again after concentrating and stir, fling to the chromatographic column upper end that is added to preparation behind the solvent, with the preparative scale chromatography post filtrating is carried out separation and purification then; Wherein the moving phase used of chromatographic column is 3: 7 the acetonitrile and the mixing solutions of water as volume ratio, and flow velocity 1.5ml/min, fixed phase stuffing are that particle diameter is that 18-32 μ m, aperture are the ICN allumina N neutral alumina of 6nm; Column temperature is a room temperature; Wavelength 312nm collects elutriant, 50 ℃ of concentrating under reduced pressure; In liquid concentrator, add pure water, stir, crystallization, 500rpm is centrifugal, and Calcium Chloride Powder Anhydrous is dry, gets ornidazole 9.40g, yield 97.39%, purity 99.65%.
Making with extra care of comparative example's 4 ornidazoles
The ornidazole dissolving crude product of 15g purity 96.52% in 120ml ethanol, is stirred, it is dissolved fully, add the gac of 0.3g then, 45 ℃ of whip attachment 15 minutes are filtered decarburization, collect filtrating; Concentrated back adds pure water, stirs, and crystallization, 500rpm is centrifugal, and Calcium Chloride Powder Anhydrous is dry, gets ornidazole 9.42g, yield 97.60%, purity 97.28%.
The foregoing description and Comparative Examples have proved absolutely the meliority of particular combination method of the present invention from different aspects, especially comprise the chromatographic condition and the optimum parameters of preparative scale chromatography post, have brought beyond thought effect, are in theory can't rational expectation.Bound by theory not; What possibly be various purification process to different impurities in the medicine removes the effect difference; The purification process of the present invention's combination has collaborative centrifugation to the impurity in the medicine; Process for purification provided by the invention has the characteristics and the obvious improvement of essence, and the beyond thought technique effect of obtaining has obtained the highly purified product of high yield.
According to the above embodiments the present invention has been made detailed description, and the present invention confirms that through relevant with it comparative example the present invention has obtained unexpected excellent effect.What need explanation is that above embodiment is just to illustrating the present invention.Under the prerequisite that does not depart from spirit of the present invention and essence, those skilled in the art can design multiple alternative of the present invention and improvement project, and it all should be understood to be within protection scope of the present invention.

Claims (7)

1. the ornidazole compound shown in the formula (I) is characterized in that its method for making may further comprise the steps:
Figure FDA0000075933330000011
(1) with a certain amount of ornidazole dissolving crude product in organic solvent, add charcoal absorption, filter, collect filtrating, concentrating under reduced pressure obtains the ornidazole of elementary purification;
(2) ornidazole with above-mentioned elementary purification carries out separation and purification with the preparative scale chromatography post, collects elutriant, and concentrating under reduced pressure obtains the ornidazole that secondary is purified;
(3) in above-mentioned liquid concentrator, add pure water, carry out crystallization, with the crystal centrifuge washing of separating out, drying, the ornidazole of three grades of purifications of acquisition.
2. the method for making of ornidazole according to claim 1 is characterized in that this method comprises the steps:
(1) with a certain amount of ornidazole dissolving crude product in the organic solvent that dissolves each other with water of 4-10 times of weight, add the gac that accounts for overall solution volume 0.1-0.5% (g/ml), 40-50 ℃ whip attachment 10-15 minute; Filter decarburization; Collect filtrating, concentrating under reduced pressure obtains the ornidazole of elementary purification;
(2) ornidazole with above-mentioned elementary purification carries out separation and purification with preparation type neutral alumina chromatographic column, collects the ornidazole elutriant, and 40~60 ℃ of concentrating under reduced pressure obtain the ornidazole that secondary is purified;
(3) in above-mentioned liquid concentrator, add pure water, carry out crystallization, the crystal centrifuge washing of separating out is dry through solid drier, the ornidazole of three grades of purifications of acquisition.
3. method for making according to claim 2 is characterized in that the organic solvent that dissolves each other with water described in the step (1) is selected from one or more in methyl alcohol, ethanol, propyl alcohol, acetone, acetonitrile, tetramethylene sulfone, hydroxy-propionic acid, the terepthaloyl moietie, is preferably ethanol.
4. according to the method for making of the ornidazole of one of claim 1-3; It is characterized in that the moving phase that chromatographic column is used in the step (2) is 3: 7 the acetonitrile and the mixing solutions of water as volume ratio, fixed phase stuffing is selected from neutral alumina, flow velocity 0.1-2ml/min; Column temperature is a room temperature, wavelength 312nm.
5. according to the method for making of the ornidazole of one of claim 1-4, it is characterized in that 50 ℃ of concentrating under reduced pressure in the step (2).
6. according to the method for making of the ornidazole of one of claim 1-5, it is characterized in that: said fixed phase stuffing is that particle diameter is 18-200 μ m, and the aperture is the pore neutral alumina of about 6nm.
7. the purposes that is used for anaerobe resistant and anti-trichomonal medicine according to the ornidazole of one of claim 1-6 method preparation in preparation.
CN 201110198551 2011-07-15 2011-07-15 Ornidazole compound and novel preparation method thereof Expired - Fee Related CN102321029B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201110198551 CN102321029B (en) 2011-07-15 2011-07-15 Ornidazole compound and novel preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201110198551 CN102321029B (en) 2011-07-15 2011-07-15 Ornidazole compound and novel preparation method thereof

Publications (2)

Publication Number Publication Date
CN102321029A true CN102321029A (en) 2012-01-18
CN102321029B CN102321029B (en) 2013-04-03

Family

ID=45448894

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201110198551 Expired - Fee Related CN102321029B (en) 2011-07-15 2011-07-15 Ornidazole compound and novel preparation method thereof

Country Status (1)

Country Link
CN (1) CN102321029B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391188A (en) * 2011-09-30 2012-03-28 山东罗欣药业股份有限公司 Ornidazole hydrate crystal, preparation method thereof and crystal-containing composition tablets
CN103073501A (en) * 2012-12-07 2013-05-01 西安万隆制药股份有限公司 Ornidazole crystal compound
CN105585532A (en) * 2014-10-24 2016-05-18 山东齐都药业有限公司 After-treatment method for levornidazole reaction liquid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1651415A (en) * 2004-11-29 2005-08-10 南京圣和药业有限公司 Preparation and purification method of ornidazole optical antipode
CN101143849A (en) * 2007-10-12 2008-03-19 西安新安医药科技有限公司 Preparation and purification method for optical enantiomer of ornidaxole
CN101633643A (en) * 2009-08-14 2010-01-27 海南美大制药有限公司 Ornidazole compound in new path

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1651415A (en) * 2004-11-29 2005-08-10 南京圣和药业有限公司 Preparation and purification method of ornidazole optical antipode
CN101143849A (en) * 2007-10-12 2008-03-19 西安新安医药科技有限公司 Preparation and purification method for optical enantiomer of ornidaxole
CN101633643A (en) * 2009-08-14 2010-01-27 海南美大制药有限公司 Ornidazole compound in new path

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391188A (en) * 2011-09-30 2012-03-28 山东罗欣药业股份有限公司 Ornidazole hydrate crystal, preparation method thereof and crystal-containing composition tablets
CN103073501A (en) * 2012-12-07 2013-05-01 西安万隆制药股份有限公司 Ornidazole crystal compound
CN105585532A (en) * 2014-10-24 2016-05-18 山东齐都药业有限公司 After-treatment method for levornidazole reaction liquid
CN105585532B (en) * 2014-10-24 2018-05-01 山东齐都药业有限公司 The post-processing approach of l-ornidazole reaction solution

Also Published As

Publication number Publication date
CN102321029B (en) 2013-04-03

Similar Documents

Publication Publication Date Title
CN102516096B (en) Refining method of hydrochloric acid ambroxol compound
CN107501045B (en) Method for separating and purifying butanetriol from fermentation liquor by using macroporous adsorption resin
CN102093302B (en) Valsartan compound and new manufacturing method thereof
CN103664989A (en) Method used for preparing moxidectin using nemadectin fermentation broth
CN102887877A (en) Method for purifying cabazitaxel
JP5180321B2 (en) Separation and purification method of epothilone
CN102321029B (en) Ornidazole compound and novel preparation method thereof
CN102558182A (en) Ertapenem sodium crystal form E and preparation method thereof
CN101824018A (en) Method for purifying dihydromyricetin
TWI488862B (en) Separation and Purification of Cyclohexyl Compounds and Their Salts
CN102268025A (en) Biapenem compound and preparation method thereof
CN104231044B (en) Process for purifying nosiheptide by passing through column
CN102702181A (en) Lafutidine compound and novel preparation method of lafutidine compound
CN102391259B (en) Nifuratel compound and preparation method thereof
CN102491940B (en) Nisoldipine compound and novel preparation method thereof
CN102367250B (en) Lansoprazole compound and novel preparation method thereof
CN102093297B (en) Telmisartan compound and new preparation method thereof
CN102351767B (en) Alprostadil compound and preparation method thereof
CN102617327A (en) Dexibuprofen compound and preparation method thereof
CN102391283B (en) Clopidogrel hydrogen sulfate compound and preparation method thereof
CN102093272B (en) Racecadotril compound and novel preparation method thereof
RU2658426C1 (en) Method for producing nicotinamide adenine dinucleotide (nad)
CN114275769B (en) Separation of C from fullerene mixture using silver salt 60 And C 70 Is a method of (2)
CN102086190B (en) Cilostazol compound and novel preparation method thereof
CN102391342B (en) Dexamethasone palmitate compound and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130403

Termination date: 20160715

CF01 Termination of patent right due to non-payment of annual fee